title: [Treatment of hemolytic uremic syndrome after acute stage].
abstract: OBJECTIVE
  Hemolytic uremic syndrome (HUS) is a common primary disease that can cause acute renal failure in childhood. Renal disease is the most important long-term complication in patients who survived the acute stage of HUS. Use of angiotensin-converting enzyme inhibitors (ACEI) and a restricted protein intake may be beneficial to the patients. However, it is not established whether such patients should be treated with steroids and immunosuppressors. The present study aimed to probe into the benefit of using steroid and immunosuppressor in patients after acute stage of HUS.
  
  
  METHODS
  The subjects included 17 patients (aged 9 months to 15 years, 12 males, 5 females) with HUS. Thirteen patients recovered from the acute stage of HUS, and underwent continuative treatment and follow-up. All the patients were treated with ACEI and early restriction of protein intake. Additionally, 2 children manifested as glomerulonephritis, one was treated with triperygium glycosides. Other 11 children who manifested as nephrotic syndrome were treated with prednisone, among them 5 children had no response or had incomplete response to prednisone, for these children short-term high dose cyclophosphamide or methylprednisolone pulse treatment were added; in 3 of the children short-term high dose methylprednisolone treatment was applied additionally for membranoproliferative glomerulonephritis and/or focal segmental glomerulosclerosis and crescentic glomerulonephritis.
  
  
  RESULTS
  After follow-up for 2 months to 8 years, 4 patients with milder disease recovered, their blood pressure, renal function and urinalysis became normal, but 1 patient had recurrence. Among 9 patients with severe disease, 6 maintained normal blood pressure, recovered renal function and urinalysis, the other 3 patients failed to comply with treatment protocol and died during the 3rd, 9th and 13th month. The remainder (4 cases) gave up therapy and died on the 27th to 48th days of the course.
  
  
  CONCLUSIONS
  The treatment applied in this study could improve the prognosis of patients after acute phase of HUS evidently by using the steroid and immuno suppressor according to clinical classification and pathological findings. It is recommended that triperygium glycosides is beneficial to children with glomerulonephritis, proteinuria and hematuria after acute stage of HUS. Adjustment of therapeutic schedule based on pathological findings after renal biopsy is helpful. To the patients with progressive renal failure who have no response to the steroid and immunosuppressors, steroid and immunosuppressor should be discontinued and dialysis treatment should be applied. Protocol compliance is also an important factor.
authors.affiliation: Department of Pediatrics, Fuzhou General Hospital of Nanjing Millitary Command, Fuzhou 350025, China.
authors.forename: Li-yan
authors.initials: LY
authors.lastname: Ye
authors.forename: Zi-hua
authors.initials: ZH
authors.lastname: Yu
authors.forename: Zu-xiong
authors.initials: ZX
authors.lastname: Huang
authors.forename: Xin-min
authors.initials: XM
authors.lastname: Chen
authors.forename: Rong-na
authors.initials: RN
authors.lastname: Ren
authors.forename: Guang-ming
authors.initials: GM
authors.lastname: Chen
authors.forename: Cheng-feng
authors.initials: CF
authors.lastname: Wang
authors.forename: Gui-zhi
authors.initials: GZ
authors.lastname: Xia
authors.forename: Juan
authors.initials: J
authors.lastname: Huang
authors.forename: Fang-jian
authors.initials: FJ
authors.lastname: Wang
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018753:Diet, Protein-Restricted; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006463:Hemolytic-Uremic Syndrome / Q000178:diet therapy* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D011379:Prognosis; D013256:Steroids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007166:Immunosuppressive Agents; D013256:Steroids